18f-alfatide ii - a radiotracer composed of a pegylated, dimeric arginine-glycine-aspartic acid (rgd) peptide (prgd2), radiolabeled, via the chelating agent 1,4,7-triazacyclononane-n,n',n-triacetic acid (nota), to a fluorine f 18-aluminum complex (alf), with potential alphavbeta3 integrin (vitronectin receptor) imaging activity using positron emission topography (pet). Upon administration, the rgd moiety of fluorine f 18 alfatide ii selectively binds to alphavbeta3 integrin. During pet, alphavbeta3-expressing tumor cells can be visualized and the degree of tumor angiogenesis can be determined. Alphavbeta3 integrin, a cell adhesion and signaling receptor, is upregulated in tumor vessel endothelial cells and has been associated with neovascularization, differentiation, proliferation of tumor cells, and metastasis. Pegylation provides improved drug penetration into tumors and decreases drug clearance, thereby increasing efficacy while lowering systemic toxicity.
Up to date info
Latest research - 18f-alfatide ii
|This medical article is a stub. You can help WikiMD by expanding it.|
Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on 18f-alfatide ii for any updates.